Advertisement

Ethical Reflections in Genetic Screening: A Reply to Swint and Kaback

  • Stuart F. Spicker
Part of the Philosophy and Medicine book series (PHME, volume 21)

Abstract

Before replying to the contribution of J. Michael Swint and Michael M. Kaback, in their “Intervention Against Genetic Disease: Economic and Ethical Considerations,” it may be useful to consider their examination of the economic and ethical consequences of three genetic screening programs in the wider context of a prominent dilemma which is presently confronting the public, virtually all health professionals, the United States government, and even the entire market economy ([2],[3]). In the present context, where we have been asking what, if anything, is the price of health, it may be useful to formulate the central predicament which is now upon us, and to appreciate the fact that two equally distasteful conclusions or outcomes are about to be realized.

Keywords

Screen Program Neural Tube Defect Average Life Expectancy Mount Sinai Hospital United States Government 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. [1]
    Beauchamp, T. L. and Childress, J. F.: 1983, Principles of Biomedical Ethics, 2nd edition, Oxford University Press, New York.Google Scholar
  2. [2]
    Enthoven, A. C.: 1978, ‘Consumer-Choice Health Plan: Inflation and Inequity in Health Care Today’, New England Journal of Medicine 298, 650–658.CrossRefGoogle Scholar
  3. [3]
    Enthoven, A. C.: 1978, ‘Consumer-Choice Health Plan: A National-Health Insurance Proposal Based on Regulated Competition in the Private Sector’, New England Journal of Medicine 298, 709–720.CrossRefGoogle Scholar
  4. [4]
    Graven, D., et al.: 1984, The Price of Life: Ethics and Economics: Report of the Task Force on the Affordability of New Technology and Highly Specialized Care: Life at Any Price?, Minnesota Coalition on Health Care Costs, Minneapolis, Minnesota.Google Scholar
  5. [5]
    Halper, T.: 1985, ‘Life and Death in a Welfare State: End-stage Renal Disease in the United Kingdom’, Milbank Memorial Fund Quarterly 63, 52–93.CrossRefGoogle Scholar
  6. [6]
    Heckler, M. M., et al.: 1985, ‘Ethics, Rationing and Economic Reality’, Federation of American Hospitals Review 18, 14–43.Google Scholar
  7. [7]
    Hilton, B., et al.: 1973: Ethical Issues in Human Genetics, Plenum Press, New York.Google Scholar
  8. [8]
    Mount Sinai Hospital Annual Report: 1984, ‘No Easy Answers: The Issue of Medical Ethics’, Mount Sinai Hospital, Hartford, Connecticut.Google Scholar
  9. [9]
    President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research: 1983, Screening and Counseling for Genetic Conditions: A Report on the Ethical, Social, and Legal Implications of Genetic Screening, Counseling, and Education Programs: U.S. Government Printing Office, Washington, D.C.Google Scholar
  10. [10]
    Twiss, S. B.: 1974, ‘Ethical Issues in Genetic Screening: Models of Genetic Responsibility’, in Bergsma, et al. (eds.), Ethical, Social and Legal Dimensions of Screening for Human Genetic Disease, Stratton Intercontinental Medical Book Corp., New York, pp. 220–261.Google Scholar

Copyright information

© D. Reidel Publishing Company 1986

Authors and Affiliations

  • Stuart F. Spicker
    • 1
  1. 1.School of MedicineUniversity of Connecticut Health CenterFarmingtonUSA

Personalised recommendations